PRAX News and Press, Praxis Precision Medicines Inc. From 05/11/23

2023-05-11 09:29:59 ET More economic data, earnings reports, performance outlooks from management teams, and the Federal Reserve are driving sentiment in the stock market today. Whether you’re trading penny stocks or higher-priced company shares, there’s no getting around ...

Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for focal epilepsy Cash and investments of $85.8 million as of March ...

PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider than current market leader based on MES model Phase 1 results support preclinical profile ...

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

2023-04-17 15:24:51 ET Thanks to an explosion of interest in penny stocks , plenty of stocks under $5 are gaining momentum in the stock market today. Whether you’re looking for short squeeze stocks, low float stocks, or simply hunting for a list of penny stocks in a specific sect...

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

2023-04-10 03:24:51 ET Summary Praxis Precision Medicines' ulixacaltamide (PRAX-944) fails to achieve statistical significance in primary endpoint for essential tremor treatment in Phase 2 clinical trial. The drug demonstrates nominal statistical significance in secondary endpoint...

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

Gainers: Altamira Therapeutics ( CYTO ) +86% . Bullfrog AI ( BFRG ) +26% . Seer ( SEER ) +25% . Ardelyx ( ARDX ) +23% . Lucy Scientific Discovery ( LSDI ) +16% . Losers: Praxis Precision Medicines ( PRAX ) -55% . Veru (...

Praxis Precision Medicines PRAX -49% after mid-stage data for movement disorder candidate . Veru VERU -34% after Veru COVID respiratory treatment sabizabulin declined authorization by FDA . Cidara Therapeutics ( CDTX ) -17% on launching concurrent but separa...